SUPERNUS PHARMACEUTICALS, INC.

Delisted

CIK 1356576fmd_1YB15T5FAH2DM8Q9HRQY1KV5WXManufacturing · Pharmaceutical PreparationsTemplate: Standard

Coverage: Jan 01, 2010 to Sep 30, 2026, 64 periods

Income Statement · Annual · Millions · USD
Line item	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025
Total revenues	215	302	409	393	520	580	667	608	662	719
Cost of revenue	12	15	15	17	52	–	87	84	78	75
Gross profit	203	287	394	376	468	–	580	524	584	644
Research and development	43	50	89	69	76	90	75	92	109	106
Selling, general and administrative	106	138	155	153	201	305	377	336	322	486
Operating income	54	100	144	149	174	86	46	(5)	82	(62)
Interest expense	1	0	14	18	19	20	7	2	0	0
Interest and investment income	1	3	14	–	–	–	–	–	–	–
Other non-operating income (expense)	(4)	1	(4)	(1)	(5)	(13)	15	8	16	13
Income before taxes	50	101	140	147	169	73	61	3	98	(49)
Income tax expense	(41)	43	29	34	42	20	0	1	24	(10)
Net income from continuing operations	91	57	111	113	127	53	61	1	74	(39)
Net income	91	57	111	113	127	53	61	1	74	(39)
Net income to common shareholders	91	57	111	113	127	53	64	1	74	(39)